Jessica Wilden
Neurological Surgery · Shreveport, LANPI 1962565127
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,875 of the $57,299 with a category attached, or 64.4%. Clearpoint Neuro, Inc. accounts for 83.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $33,118 and has fallen 98.5% since, to $485 in 2023.
Across 288 payments — averaging $198.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Clearpoint Neuro, Inc.$48K
- Medtronic$5K
- Insightec,inc$1K
- Acadia Pharmaceuticals Inc$963
- Boston Scientific$856
- Abbott$714
- plus $803 from 11 others
Across 30 payments — averaging $1358.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$41K
What the payments were for
- Consulting fees$36,87564%
- Travel & lodging$13,34723%
- Food & beverage$7,07712%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Clearpoint Neuro, Inc. | 45 | $47,727 |
| Medtronic(2 entities) | 50 | $4,767 |
| Insightec,inc | 3 | $1,470 |
| Acadia Pharmaceuticals Inc | 94 | $963 |
| Boston Scientific | 33 | $856 |
| Abbott | 16 | $714 |
| AbbVie | 19 | $214 |
| MDD US Operations, LLC | 5 | $177 |
| Amneal Pharmaceuticals LLC | 9 | $173 |
| Sunovion Pharmaceuticals Inc. | 5 | $57 |
| Kyowa Kirin, Inc. | 2 | $44 |
| Portola Pharmaceuticals, LLC | 1 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Sanara Medtech Inc. | 2 | $23 |
| Adamas Pharmaceuticals, Inc. | 1 | $22 |
| Siemens Medical Solutions USA, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLEARPOINT$29,656
- ClearPoint System$17,497
- VISUALASE$2,154
- Exablate$1,392
- PERCEPT PC BRAINSENSE$748
- SenSight$175
- Infinity DBS Pulse Generators$156
- Neuromodulation Dspsbls and Accs$119
- APOKYN$112
How this compares
$57,299 in reported general payments places this provider in the 80th percentile of 116 neurological surgery providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 21 | $14,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $173 | $14,67421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 116 neurological surgery providers in Louisiana.
Other neurological surgery in Shreveport
- Anthony SinShreveport$1.5M
- Ravish PatwardhanShreveport$120K
- Stanley HoangShreveport$88K
- Peter CampbellShreveport$76K
- Jamie TomsShreveport$17K
- Sungho LeeShreveport$6K
- Sebastian KogaHammond$720K
- Eric OberlanderBaton Rouge$660K
- Najeeb ThomasMetairie$440K
- Gabriel TenderNew Orleans$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.